GlobeNewswire

Aligos Therapeutics To Present at the Piper Sandler Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO of Aligos, and the Aligos management team, will present at the 2023 Piper Sandler Healthcare Conference being held in New York on Thursday, November 30, 2023 at 12:30 p.m. ET.

Piper Sandler Healthcare Conference Information:

 Date Thursday, November 30, 2023  
 Time: 12:30 p.m. ET  
 Presenter: Lawrence Blatt, Ph.D., MBA, CEO of Aligos  
 Webcast: Link here  

A replay of the session will be available following the conference for 90-days through the Aligos investor section of the website https://investor.aligos.com/.

The Aligos management team will also participate in investor 1x1 meetings during the conference. Please contact your Piper Sandler representative to schedule one-on-one meetings with Aligos during the conference.

About Aligos

Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of liver and viral diseases. Aligos’ strategy is to harness the deep expertise and decades of drug development experience its team has in liver and viral diseases to discover and develop potentially best in class therapeutics for nonalcoholic steatohepatitis (NASH) and viruses with high unmet medical need such as coronaviruses and chronic hepatitis B (CHB).

Media Contact
Veronica Eames
LifeSci Communications
veames@lifescicomms.com

Investor Contact
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com


Primary Logo

NOTE: This content is not written by or endorsed by "KXMA", its advertisers, or Nexstar Media Inc.

For inquiries or corrections to Press Releases, please reach out to GlobeNewswire.